One in five patients achieve functional hepatitis B cure after 24 weeks of bepirovirsen

medicalxpress - In an editorial published in the New England Journal of Medicine, University of Michigan Health hepatologist Anna S. Lok, M.D., hails newly announced results of the B-Well clinical trials as "a major step toward a functional cure for hepatitis B virus inf…

AI Summary: An antisense therapy, bepirovirsen, produced functional cures in roughly one in five patients after 24 weeks, driving cautious optimism for a finite treatment for chronic hepatitis B. The study demonstrated significant viral declines and serologic changes in a subset, prompting larger trials to confirm durability, safety, and which patients actually benefit.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Antiviral ensitrelvir dramatically cuts household COVID transmission risk / 15 days

Favipiravir shows promise in Lassa fever Phase 2 trial / 15 days

Moderna launches mRNA bird‑flu vaccine trial as preparedness ramps up / 5 wks

FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 13 days

Gene therapy pioneers win Breakthrough Prize for CRISPR sickle‑cell work / 6 wks

First‑in‑human CRISPR/Cas12a sickle cell therapy treated; gene editing shows promise / 1 month

Denali drug receives accelerated approval for rare CNS indication / 2 months